Expert Ratings for Warner Bros.Discovery

Over the past 3 months, 6 analysts have published their opinion on Warner Bros.Discovery (NASDAQ:WBD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Over the past 3 months, 6 analysts have published their opinion on Warner Bros.Discovery (NASDAQ:WBD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company’s business to predict how a stock will trade over the upcoming year.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 1 4 0 0
Last 30D 0 0 1 0 0
1M Ago 0 1 1 0 0
2M Ago 0 0 1 0 0
3M Ago 1 0 1 0 0

These 6 analysts have an average price target of $19.5 versus the current price of Warner Bros.Discovery at $10.245, implying upside.

Below is a summary of how these 6 analysts rated Warner Bros.Discovery over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average represents a 20.96% decrease from the previous average price target of $24.67.

Stay up to date on Warner Bros.Discovery analyst ratings.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Analysts Eye Summit Therapeutics’ Ivonescimab As Potential Challenger To Merck’s Keytruda in Lung Cancer Treatment

Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in 2024 and a $5 billion deal add to the optimism, signaling potential share price growth ahead.

MRK